[ HARMONIZER — NOT A MARKET ]
Produces the guidelines member authorities implement in their own law. Nothing is sold into ICH; its output arrives through a national regulator adopting it.
SPEQ synthesis for orientation. It does not determine what applies to a specific product, and an adopted version can move without this page moving with it. Confirm the instrument in force with the authority before relying on it.
INTERNATIONAL
None of its own, and that is the first thing to understand about it. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use has been a non-profit legal entity under Swiss law, headquartered in Geneva, since October 2015 — before that it was the International Conference on Harmonisation, a tripartite initiative rather than an organisation. Its legal personality lets it hold members and run a secretariat. It does not let it make law anywhere, and the guidelines it publishes bind nobody until a regulator adopts them.
By regional adoption, one authority at a time, and the adopted instrument is what a practitioner is actually held to. Regulatory members are expected to implement the guidelines in their own systems: FDA issues them as guidance for industry, the European Union brings them in through CHMP and the Commission, Japan by MHLW notification. The consequence is that “ICH Q9(R1) requires” is a shorthand rather than a citation — the requirement, and its exact version and effective date, belongs to whichever authority adopted it in the market being addressed.
WHAT TRANSFERS
The technical expectation transfers well; the timing does not. Because adoption is regional and sequential, two markets can sit on different versions of the same guideline for a period, and a submission written against the newest ICH text may reference expectations one of them has not yet implemented. What transfers most reliably is the Common Technical Document structure under M4, which is why a dossier assembled once can be filed in several regions with regional modules swapped rather than rebuilt. Structure travels further than content.
Quality (Q), Safety (S), Efficacy (E) and Multidisciplinary (M). Q covers manufacturing and quality — Q7 for active substances, Q9(R1) for risk management, Q10 for the pharmaceutical quality system, Q12 for lifecycle change. E covers clinical, including E6 for good clinical practice. M carries what fits nowhere else, including the CTD.
For a regulatory commitment, a deviation justification or an inspection response, the citable authority is the regional adoption — an FDA guidance, an EMA-adopted guideline, an MHLW notification. Quoting the ICH document alone leaves the reader to establish whether it applies here, which is the question that was being asked.
ICH distinguishes founding regulatory and industry members from later regulatory members, observers and standing observers. A regulator being “in ICH” therefore says less than it appears to about what it has implemented; the adoption record for the specific guideline is the fact to check.
ICH harmonises what evidence is expected and how it should be generated. It does not harmonise application procedures, fees, timelines or the legal status of an authorisation — those stay national, which is why a harmonised dossier still meets very different administrative processes on arrival.
Not by itself. ICH is a non-profit association under Swiss law and has no legislative power in any country. A guideline acquires force only where a regulatory authority adopts it — as an FDA guidance for industry, through EU adoption, by MHLW notification, and so on. The adopted regional instrument, with its own version and effective date, is what a practitioner is held to.
They are the four guideline series: Quality, Safety, Efficacy and Multidisciplinary. Q holds the manufacturing and quality set — Q7, Q9(R1), Q10, Q12 among them; E holds clinical topics including E6 on good clinical practice; M holds cross-cutting work, most visibly the Common Technical Document at M4.
It was reformed in October 2015 into a non-profit legal entity under Swiss law, based in Geneva, with a broader membership than the three founding regions. The change of name from International Conference to International Council marks that reform; a document citing the Conference is describing the pre-2015 arrangement.
Not necessarily. Adoption is regional and sequential, so two authorities can be on different versions of the same guideline at the same time, and neither is wrong. Check the adoption record for the specific guideline in the specific market rather than treating “ICH member” as an answer.
ADOPTED, AT A PINNED VERSION
SPEQ has not decoded a pinned adoption edge here yet. That is a gap in this catalog, not a finding about ICH: requirements still arrive through the authorities that adopt this body’s output, and the edition in force is theirs to state.
Derived from the markets themselves, so this list cannot disagree with their pages.